These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 29902648)

  • 1. Maintenance Treatment Of Eosinophilic Esophagitis With Swallowed Topical Steroids Alters Disease Course Over A 5-Year Follow-up Period In Adult Patients.
    Greuter T; Safroneeva E; Bussmann C; Biedermann L; Vavricka SR; Katzka DA; Schoepfer AM; Straumann A
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):419-428.e6. PubMed ID: 29902648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and Safety of High- vs Low-Dose Swallowed Topical Steroids for Maintenance Treatment of Eosinophilic Esophagitis: A Multicenter Observational Study.
    Greuter T; Godat A; Ringel A; Almonte HS; Schupack D; Mendoza G; McCright-Gill T; Dellon ES; Hirano I; Alexander J; Chehade M; Safroneeva E; Bussmann C; Biedermann L; Schreiner P; Schoepfer AM; Straumann A; Katzka DA
    Clin Gastroenterol Hepatol; 2021 Dec; 19(12):2514-2523.e2. PubMed ID: 32798703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Treatment of Eosinophilic Esophagitis With Swallowed Topical Corticosteroids: Development and Evaluation of a Therapeutic Concept.
    Greuter T; Bussmann C; Safroneeva E; Schoepfer AM; Biedermann L; Vavricka SR; Straumann A
    Am J Gastroenterol; 2017 Oct; 112(10):1527-1535. PubMed ID: 28719593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Swallowed Fluticasone Propionate Is an Effective Long-Term Maintenance Therapy for Children With Eosinophilic Esophagitis.
    Andreae DA; Hanna MG; Magid MS; Malerba S; Andreae MH; Bagiella E; Chehade M
    Am J Gastroenterol; 2016 Aug; 111(8):1187-97. PubMed ID: 27325220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent insights on the use of topical steroids in eosinophilic esophagitis.
    Reddy A; Ashat D; Murali AR
    Expert Rev Gastroenterol Hepatol; 2020 Oct; 14(10):953-963. PubMed ID: 32567417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical steroids in eosinophilic esophagitis: Systematic review and meta-analysis of placebo-controlled randomized clinical trials.
    Murali AR; Gupta A; Attar BM; Ravi V; Koduru P
    J Gastroenterol Hepatol; 2016 Jun; 31(6):1111-9. PubMed ID: 26699695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and Therapeutic Long-term Management of Eosinophilic Esophagitis- Current Concepts and Perspectives for Steroid Use.
    Greuter T; Alexander JA; Straumann A; Katzka DA
    Clin Transl Gastroenterol; 2018 Dec; 9(12):e212. PubMed ID: 30802222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel corticosteroid formulations in the treatment of eosinophilic esophagitis: what is the evidence?
    Walgraeve S; Vanuytsel T
    Acta Gastroenterol Belg; 2023; 86(3):437-448. PubMed ID: 37814560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Close follow-up is associated with fewer stricture formation and results in earlier detection of histological relapse in the long-term management of eosinophilic esophagitis.
    Bon L; Safroneeva E; Bussmann C; Biedermann L; Schreiner P; Vavricka SR; Schoepfer AM; McCright-Gill T; Simon HU; Straumann A; Chehade M; Greuter T
    United European Gastroenterol J; 2022 Apr; 10(3):308-318. PubMed ID: 35384368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of eosinophlic esophagitis with swallowed topical corticosteroids.
    Nennstiel S; Schlag C
    World J Gastroenterol; 2020 Sep; 26(36):5395-5407. PubMed ID: 33024392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis.
    Straumann A; Conus S; Degen L; Frei C; Bussmann C; Beglinger C; Schoepfer A; Simon HU
    Clin Gastroenterol Hepatol; 2011 May; 9(5):400-9.e1. PubMed ID: 21277394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Assessment of Adult Patients' Satisfaction with Various Eosinophilic Esophagitis Therapies.
    Safroneeva E; Hafner D; Kuehni CE; Zwahlen M; Trelle S; Biedermann L; Greuter T; Vavricka SR; Straumann A; Schoepfer AM
    Int Arch Allergy Immunol; 2020; 181(3):211-220. PubMed ID: 31865318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Swallowed topical corticosteroids reduce the risk for long-lasting bolus impactions in eosinophilic esophagitis.
    Kuchen T; Straumann A; Safroneeva E; Romero Y; Bussmann C; Vavricka S; Netzer P; Reinhard A; Portmann S; Schoepfer AM
    Allergy; 2014 Sep; 69(9):1248-54. PubMed ID: 24894658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinant factors for first-line treatment choice and effectiveness in pediatric eosinophilic esophagitis: an analysis of the EUREOS EoE CONNECT registry.
    Navarro P; Feo-Ortega S; Casabona-Francés S; Gutiérrez-Junquera C; Savarino EV; Amorena E; Fernández-Fernández S; Pérez-Martínez I; Oliva S; Barrio J; Masiques-Mas ML; Guardiola-Arévalo A; Guagnozzi D; Racca F; Betoré E; Votto M; Rodríguez-Sánchez A; Barrio ML; Blas-Jhon L; Sánchez-Vegazo CT; García-Morales N; Krarup AL; Dainese R; Martín-Dominguez V; García-Díaz A; Maniero D; Santander C; Arias Á; Laserna-Mendieta EJ; Lucendo AJ
    Eur J Pediatr; 2024 Aug; 183(8):3567-3578. PubMed ID: 38819501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of Fluticasone to Budesonide in the Treatment of Eosinophilic Esophagitis.
    Albert D; Heifert TA; Min SB; Maydonovitch CL; Baker TP; Chen YJ; Moawad FJ
    Dig Dis Sci; 2016 Jul; 61(7):1996-2001. PubMed ID: 27093866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Budesonide Oral Suspension Maintenance Therapy in Patients With Eosinophilic Esophagitis.
    Dellon ES; Katzka DA; Collins MH; Gupta SK; Lan L; Williams J; Hirano I
    Clin Gastroenterol Hepatol; 2019 Mar; 17(4):666-673.e8. PubMed ID: 29902649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review.
    Ma C; van Rhijn BD; Jairath V; Nguyen TM; Parker CE; Aceves SS; Furuta GT; Gupta SK; Katzka DA; Safroneeva E; Schoepfer AM; Straumann A; Spergel JM; Pai RK; Feagan BG; Hirano I; Dellon ES; Bredenoord AJ
    Clin Gastroenterol Hepatol; 2018 Nov; 16(11):1714-1729.e3. PubMed ID: 29908360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton pump inhibitor therapy reverses endoscopic features of fibrosis in eosinophilic esophagitis.
    Navarro P; Laserna-Mendieta EJ; Guagnozzi D; Casabona S; Perelló A; Savarino E; de la Riva S; Olalla JM; Ghisa M; Serrano-Moya N; Alcolea-Valero C; Ortega-Rabbione G; Majano P; Santander C; Arias Á; Lucendo AJ;
    Dig Liver Dis; 2021 Nov; 53(11):1479-1485. PubMed ID: 34120859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eosinophilic esophagitis--treatment of eosinophilic esophagitis with drugs: corticosteroids.
    von Arnim U; Malfertheiner P
    Dig Dis; 2014; 32(1-2):126-9. PubMed ID: 24603395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Montelukast Does not Maintain Symptom Remission After Topical Steroid Therapy for Eosinophilic Esophagitis.
    Alexander JA; Ravi K; Enders FT; Geno DM; Kryzer LA; Mara KC; Smyrk TC; Katzka DA
    Clin Gastroenterol Hepatol; 2017 Feb; 15(2):214-221.e2. PubMed ID: 27650328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.